A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by American Medical Systems.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
American Medical Systems
ClinicalTrials.gov Identifier:
NCT00998790
First received: October 8, 2009
Last updated: March 31, 2011
Last verified: March 2011

October 8, 2009
March 31, 2011
January 2007
May 2012   (final data collection date for primary outcome measure)
  • To obtain procedural technique data for use in physician education and training [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • To collect clinical outcomes data for future publication [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00998790 on ClinicalTrials.gov Archive Site
  • To record adverse events at implant and follow-up time-points [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • To characterize incontinence severity at specified time-points [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • To evaluate patient quality of life [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence
A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence

A prospective, multi-center study of the AdVance Male Sling for Stress Urinary Incontinence. The purpose of this study is to obtain surgical technique data for use in physician education and training and to collect early clinical outcomes data for future publication. This study is not designed to statistically demonstrate safety and efficacy of the device.

A prospective, multi-center study conducted under a common implant and follow-up protocol. The study will collect pre-operative urologic testing, medical history and subject quality of life (Incontinence Quality of Life Questionaire). Intra-operative procedural data will be collected.

Pad weight and incontinence severity rating (using the ICIQ survey) will be used to characterize continence status.

Post-operative complications, urologic testing, and subject quality of life will be collected at six weeks and three, six, 12, and 24 months.

Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Urinary Incontinence, Stress
Device: American Medical Systems (AMS) AdVance™ Male Sling System
The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
Other Name: Device: AdVance Male Sling
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
113
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The subject has agreed to be implanted with the AMS AdVance Male Sling System.
  2. The subject is willing and able to give valid informed consent.
  3. The subject is ≥40 years of age.
  4. The subject has confirmed stress urinary incontinence for at least 6 months and uses no more than 8 pads per day for incontinence management and has less than 250 grams on the 24-hour pad weight test.
  5. The subject has any of the following: an observable degree of incontinence during stress related activities, more than one pad is used in a 24 hour period, has more than two episodes of incontinence per day.
  6. Internal sphincter contractility confirmed by endoscopic view.
  7. The subject's primary etiology is TUR, TURP, or radical prostatectomy.
  8. Pre-existing urological conditions, other than incontinence have been treated and are under control.
  9. The subject is willing and able to return for follow-up evaluations and questionnaire completion according to the study protocol.
  10. The subject is a good surgical candidate.

Exclusion Criteria:

  1. The subject has a neurogenic bladder condition that is not treatable or controllable by pharmacological or alternative methods.
  2. The subject has a post-void residual ≥ 100 cc.
  3. The subject has detrusor-external sphincter dyssynergia.
  4. The subject has a urinary tract infection (UTI).
  5. The subject was treated with pelvic radiation within the last 6 months.
  6. The subject currently has an inflatable penile prosthesis.
  7. The subject self-catheterizes.
  8. The subject has symptomatic or unstable bladder neck structure disease.
  9. The subject has a history of urethral strictures that may require repetitive instrumentation.
  10. The subject has previously had a urethral Sling System, an AMS Sphincter 800™, or any implanted device for the treatment of urinary incontinence (not including bulking agents).
  11. The subject has a history of connective tissue or autoimmune conditions.
  12. The subject has a compromised immune system.
  13. The subject has renal insufficiency, and upper and/or lower urinary tract relative obstruction.
  14. The subject's reading level is judged inadequate for reading and understanding the quality of life questionnaires and other study materials.
Male
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France,   Belgium
 
NCT00998790
MC0602
No
Tim De Groot, Sr. Clinical Program Manager, American Medical Systems
American Medical Systems
Not Provided
Principal Investigator: Armin Becker, MD Oberarzt der Urologischen Klinik Grosshadern
Principal Investigator: Dirk de Ridder, Professor UZ Gasthuisberg
Principal Investigator: Pedro Arano, MD Fundacion Puigvert
Principal Investigator: Francois Haab, Professor Institution Tenon Hospital
Principal Investigator: Olivier Haillot, Professor Hopital Bretonneau
Principal Investigator: Philippe Chauveau, MD Clinique Jules Verne
Principal Investigator: Hakim Fassi-Fehri, MD Hopital Edouard Herriot
American Medical Systems
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP